COMPANY
Evergreen Theragnostics
Evergreen Theragnostics manufactures radiopharmaceuticals for partner companies and registers and commercializes its own radiopharmaceutical products, with a focus on cancer. From company website Source · Oct 12, 2026
Trial and FDA signals
- FDA complete response letter Received an FDA complete response letter (NDA 216900, letter dated Jun 26, 2026). FDA NDA 216900 (Jun 26, 2026)
Evidence (1 event)
- Jun 26, 2026 · FDA NDA 216900
CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Evergreen Theragnostics, Inc. C/o Bourque Regulatory CMC, Inc. Attention: Mr. Jeffrey Bourque President, Bourque Regulatory CMC, Inc. Springfield, NJ (street omitted) Dear Mr
- Jun 26, 2026 · FDA NDA 216900